SE0101082D0 - Novel use - Google Patents

Novel use

Info

Publication number
SE0101082D0
SE0101082D0 SE0101082A SE0101082A SE0101082D0 SE 0101082 D0 SE0101082 D0 SE 0101082D0 SE 0101082 A SE0101082 A SE 0101082A SE 0101082 A SE0101082 A SE 0101082A SE 0101082 D0 SE0101082 D0 SE 0101082D0
Authority
SE
Sweden
Prior art keywords
novel use
prophylaxis
pain
compounds
useful
Prior art date
Application number
SE0101082A
Other languages
English (en)
Swedish (sv)
Inventor
Sverker Hanson
Gunnar Nordvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101082A priority Critical patent/SE0101082D0/xx
Publication of SE0101082D0 publication Critical patent/SE0101082D0/xx
Priority to US10/472,992 priority patent/US7067657B2/en
Priority to AT02713341T priority patent/ATE370147T1/de
Priority to JP2002576248A priority patent/JP2004524351A/ja
Priority to PCT/SE2002/000599 priority patent/WO2002076990A1/en
Priority to ES02713341T priority patent/ES2290277T3/es
Priority to AU2002245005A priority patent/AU2002245005A1/en
Priority to EP02713341A priority patent/EP1377590B1/de
Priority to DE60221813T priority patent/DE60221813T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0101082A 2001-03-27 2001-03-27 Novel use SE0101082D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use
US10/472,992 US7067657B2 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor
AT02713341T ATE370147T1 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
JP2002576248A JP2004524351A (ja) 2001-03-27 2002-03-26 新規な使用
PCT/SE2002/000599 WO2002076990A1 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
ES02713341T ES2290277T3 (es) 2001-03-27 2002-03-26 Derivados de tiazolopirimidina y su uso como antagonistas del receptor cx3cr1.
AU2002245005A AU2002245005A1 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
EP02713341A EP1377590B1 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
DE60221813T DE60221813T2 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use

Publications (1)

Publication Number Publication Date
SE0101082D0 true SE0101082D0 (sv) 2001-03-27

Family

ID=20283552

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use

Country Status (9)

Country Link
US (1) US7067657B2 (de)
EP (1) EP1377590B1 (de)
JP (1) JP2004524351A (de)
AT (1) ATE370147T1 (de)
AU (1) AU2002245005A1 (de)
DE (1) DE60221813T2 (de)
ES (1) ES2290277T3 (de)
SE (1) SE0101082D0 (de)
WO (1) WO2002076990A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313632D0 (en) * 2003-06-12 2003-07-16 Neuro Targets Ltd Chemokine receptors
EP1520586A1 (de) * 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibierung von Fractalkin oder von dessen Rezeptor zur Behandlung von atopishen Allergien
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1806145B1 (de) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Mittel zur behandlung von entzündlichen erkrankungen
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
US20100215663A1 (en) * 2006-02-15 2010-08-26 Northwestern University Methods and compositions for regulation of neurological conditions
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
CN101522693B (zh) 2006-09-29 2012-01-04 阿斯利康(瑞典)有限公司 5，7-二取代的[1，3]噻唑并[4，5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2913060A1 (de) 2014-02-28 2015-09-02 Universite De Nice Sophia-Antipolis Hemmung der Fraktalkin-Rezeptorinteraktion zur Behandlung von atopischer Dermatitis
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines

Also Published As

Publication number Publication date
WO2002076990A8 (en) 2002-11-14
EP1377590A1 (de) 2004-01-07
AU2002245005A1 (en) 2002-10-08
EP1377590B1 (de) 2007-08-15
ATE370147T1 (de) 2007-09-15
US20040106628A1 (en) 2004-06-03
ES2290277T3 (es) 2008-02-16
JP2004524351A (ja) 2004-08-12
WO2002076990A1 (en) 2002-10-03
US7067657B2 (en) 2006-06-27
DE60221813D1 (de) 2007-09-27
DE60221813T2 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
BR0109703A (pt) Derivados de piperazina
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
GB0225475D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DK1379246T3 (da) Nocieptin-analoger
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
BR0113590A (pt) 7-oxo-piridopirimidinas
AU2002245005A1 (en) Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
IL173377A0 (en) Compounds for the treatment of metabolic disorders
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
SE0200198D0 (sv) New use
IL172290A0 (en) Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
SE0002739D0 (sv) New use
SE0004827D0 (sv) Therapeutic compounds